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Dear Editor,
Macroautophagy (hereafter, autophagy) is a membrane-
trafficking process that delivers cargos to lysosomes for
degradation.1 The process preserves cellular integrity by
facilitating removal of damaged proteins and organelles,
thereby protecting against various forms of disease. The
involvement of autophagy in cancer, however, is context-
specific.2 For example, work by ourselves and others has
shown that progression of certain KRAS-driven cancers,
including pancreatic ductal adenocarcinoma (PDAC), requires
autophagy for full development of disease.3–5 However, in
tumors driven by oncogenic KRAS and deletion of p53, loss of
autophagy does not block pancreatic tumor development and
even accelerates the disease.5
This caused us to question if autophagy’s contribution to
PDAC development is specifically controlled by p53 or if other
genetic lesions can also modulate autophagy’s role in this
disease. To test this hypothesis, we examined the impact of
autophagy loss in a different model of PDAC driven by
oncogenic KRAS (G12D) combined with deficiency of the
tumor suppressor, Phosphatase and Tensin Homolog (PTEN)
—a factor lost in PDAC, albeit with a relatively low frequency.6
Four cohorts of mice were generated with the following
genotypes: (1) Pdx1-Cre KRasG12D/wt Ptenwt/− Atg7wt/wt; (2)
Pdx1-Cre KRasG12D/wt Ptenwt/− Atg7− /−; (3) Pdx1-Cre
KRasG12D/wt Pten− /− Atg7wt/wt; and (4) Pdx1-Cre KRasG12D/wt
Pten− /− Atg7− /− (Supplementary Figure 1a).
Consistent with previous studies, tumors formed in
Pdx1-Cre KRasG12D/wt Ptenwt/− Atg7wt/wt mice
(Supplementary Figure 1b).6 However, in contrast to what
we and others have observed in tumors containing mutant
KRas as the only genetic lesion,3–5 deletion of the critical
autophagy regulator Atg7 did not block formation of PDAC in
animals that were also hemizygous for Pten in their pancreas
(Supplementary Figure 1b). In fact,Pten hemizygosity not only
permitted tumor formation in the absence of Atg7, but loss of
autophagy in this context caused earlier death associated with
pancreatic tumor formation when compared with autophagy-
competent animals (Supplementary Figure 1b). Importantly,
as is routinely undertaken to diagnose PDAC,7 we performed
histological analysis of tissue morphology, which showed that
both autophagy-competent and -deficient animals developed
PDAC and that tumors from Pdx1-Cre KRasG12D/wt Ptenwt/−
Atg7− /− mice lacked ATG7 expression, were deficient in LC3
puncta formation, had a strong diffuse LC3 stain indicative of
accumulation of the LC3-I form of the protein,5 and had high
levels of the adapter protein p62/SQSTM1—all signs that
these tumors were indeed autophagy-deficient. In line with
previous studies,8 these tumors were also negative for
PTEN (Supplementary Figure 1b) and importantly were also
wild-type for p53 (data not shown).
We also examined the impact of deleting both alleles ofPten
on pancreatic tumor formation driven by oncogenic KRAS in
either the absence or presence of Atg7. This revealed that
autophagy-deficient tumors (which lack LC3 puncta and
accumulate p62) can also form in the total absence of PTEN
(Supplementary Figure 1c), but loss of Atg7 did not accelerate
tumor onset in this context. It is possible, however, that the
extremely rapid onset of tumor formation caused by oncogenic
KRAS and loss of PTEN (median= 13 days) does not permit
the detection of further accelerating events.
When taken together, our findings show that autophagy’s
contribution to tumor development can be determined by the
status of either Pten, p53 or other as yet unidentified factors.
In these contexts, loss of autophagy can then promote tumor
development probably through changes in metabolism, accu-
mulation of oxidative stress, DNA damage and increased
inflammation.2 It should be stated, however, that our findings
give no indication that the genetic status of p53 or Pten would
determine the response of an established tumor to amodulator
of autophagy. This is a completely different context when
compared with loss of autophagy during tumor development
and is undoubtedly an area worthy of further investigation.
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